Eugenio Marcuello

Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial

David Cunningham, István Láng, Eugenio Marcuello et al. · The Lancet Oncology · 2013 · 654 citations

Medicine, Oncology, Pharmacology +10

Phase II, Randomized Study of Concomitant Chemoradiotherapy Followed by Surgery and Adjuvant Capecitabine Plus Oxaliplatin (CAPOX) Compared With Induction CAPOX Followed by Concomitant Chemoradiotherapy and Surgery in Magnetic Resonance Imaging–Defined, Locally Advanced Rectal Cancer: Grupo Cáncer de Recto 3 Study

Carlos Fernández-Martos, Carles Pericay, Jorge Aparicio et al. · Journal of Clinical Oncology · 2010 · 434 citations · Full text

Medicine, Oncology, Surgery +16

First-Line XELOX Plus Bevacizumab Followed by XELOX Plus Bevacizumab or Single-Agent Bevacizumab as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: The Phase III MACRO TTD Study

Eduardo Díaz‐Rubio, Auxiliadora Gómez‐España, Bartomeu Massutí et al. · The Oncologist · 2012 · 212 citations · Full text

Medicine, Oncology, Pharmacology +12

Description and management of cutaneous side effects during cetuximab or erlotinib treatments: A prospective study of 30 patients

Esther Roé, Maria Pilar García Muret, Eugenio Marcuello et al. · Journal of the American Academy of Dermatology · 2006 · 145 citations

Pharmacy, Oncology, Pharmacotherapy +15

<i>p53</i> and K-<i>ras</i> Gene Mutations Correlate With Tumor Aggressiveness But Are Not of Routine Prognostic Value in Colorectal Cancer

Silvia Tórtola, Eugenio Marcuello, Isabel González‐Álvarez et al. · Journal of Clinical Oncology · 1999 · 145 citations

Medicine, Genetics, Oncology +17